R6G9 Treatment Improves Viral-Induced Neurological Disease
Background: Multiple Sclerosis (MS) is a devastating neurological disease. MS patients often experience neurologic dysfunction believed to be the result of infiltration of immune cells, inflammation of the central nervous system and eventual nerve damage. Technology: Researchers at the University of California, Irvine have identified a monoclonal antibody-based method that decreases immune cell infiltration into the CNS and improves neurological function in a mouse model of MS. Application: This antibody may offer an attractive method for reducing CNS inflammation in humans and treating inflammatory demyelinating diseases such as MS.Type of Offer: Licensing
« More Pharmaceutical Patents